- Clearmind (CMND) has signed an agreement with IMP Clinical Supply Services
- IMP will be responsible for the global clinical supply chain of Clearmind’s proprietary drug candidate CMND-100 from manufacture to the various clinical sites
- The primary end point of the trial is to find the tolerable dose and characterize the safety and effectiveness single and repeated doses of CMND-100 in healthy subjects and those with Alcohol Use Disorder
- Clearmind Medicine Inc. (CMND) opened trading at $0.78 per share
Clearmind (CMND) has signed an agreement with IMP Clinical Supply Services.
IMP will be responsible for the global clinical supply chain of Clearmind’s proprietary drug candidate CMND-100 from manufacture to the various clinical sites.
The primary end point of the trial is to find the tolerable dose and characterize the safety and effectiveness single and repeated doses of CMND-100 in healthy subjects and those with Alcohol Use Disorder.
The secondary end point is to preliminarily evaluate the efficacy of CMND-100 in reduction of drinking patterns and craving in individuals with moderate-to-severe Alcohol Use Disorder. Oral capsules will be administered once daily, for 10 consecutive days.
The biotech company’s clinical trial is expected to commence in Q2 2023 in the United States and in Israel.
IMP develops comprehensive, tailor-made clinical supply services that address all study requirements.
Clearmind is a psychedelic pharmaceutical biotech company. Its objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
Clearmind Medicine Inc. (CMND) Stock opened trading at $0.78 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.